Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Medication Changes After Renal Denervation: Current Evidence and Patient Perspectives.
J Am Heart Assoc
December 2024
Department of Cardiology West China Hospital, Sichuan University Chengdu China.
Renal denervation (RDN) is recognized as an adjunct therapy for hypertension management with a favorable and consistent blood pressure-lowering efficacy and safety profile. Alteration in medication burden is another noteworthy outcome of RDN for clinicians and patients. In this review, we summarized current clinical trials and patient perspectives, focusing on the use of antihypertensive medication (AHM) after RDN.
View Article and Find Full Text PDFClinical trials in neuromodulatory treatment of drug-resistant hypertension and the need for spinal cord stimulation trials: a PRISMA systematic review.
Bioelectron Med
December 2024
Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Background: Drug-resistant hypertension affects approximately 9-18% of the United States hypertensive population. Recognized as hypertension that is resistant to three or more medications, drug-resistant hypertension can lead to fatal sequelae, such as heart failure, aortic dissection, and other vast systemic disease. The disruption of the homeostatic mechanisms that stabilize blood pressure can be treated procedurally when medication fails.
View Article and Find Full Text PDFResponse of Blood Pressure to Renal Denervation Is Not Associated With Genetic Variants.
Hypertension
January 2025
Department of Internal Medicine III, Cardiology, Angiology, Intensive Care Medicine, Saarland University Hospital, Homburg, Germany (L.L., M.K., M.B., F.M.).
Background: Renal denervation lowers blood pressure (BP) in patients with uncontrolled hypertension. We conducted an unbiased genomic screen to identify genetic variants that may associate with BP response to renal denervation (RDN).
Methods: Patients (n=268) with uncontrolled resistant hypertension (baseline BP, 166±21/90±15 mm Hg) who underwent endovascular RDN using the Symplicity catheter (Medtronic, Inc, Santa Rosa, CA) were included.
Catheter-Based Renal Denervation for Resistant Arterial Hypertension: 10-Year Real-World Follow-Up Data.
J Clin Hypertens (Greenwich)
December 2024
Department of Cardiology, Cardiovascular Center Aalst, Aalst, Belgium.
This analysis of real-world data examines the efficacy, safety, and long-term outcomes of renal denervation in hypertensive patients for up to 10 years. Sixty-five consecutive patients underwent renal denervation (RDN) (single operator) for uncontrolled resistant hypertension. Efficacy was defined as the interindividual change of office (OBPM) and ambulatory blood pressure monitoring (ABPM) at 1, 6, 12 months, 2-4 and 5-10 years after RDN.
View Article and Find Full Text PDFBlood Pressure Control and Clinical Outcomes After Renal Denervation Through Irrigated Catheter Radiofrequency Ablation in Patients with Resistant Hypertension: A Case Series with Up to 10 Years of Follow-Up.
High Blood Press Cardiovasc Prev
November 2024
Instituto Dante Pazzanese de Cardiologia, São Paulo, SP, Brazil.
Introduction: The long-term efficacy of renal denervation (RDN) has not been extensively documented.
Aim: To describe the long-term follow-up of patients after RDN.
Methods: We evaluated patients with resistant hypertension (RH) who underwent RDN with irrigated catheter from 2012 to 2014 at a single centre.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!